Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Echinacea purpurea for the Long-term Prevention of Viral Respiratory Tract Infections during COVID-19 Pandemic: A Randomized, Open, Controlled, Exploratory Clinical Study

Emil Kolev, Lilyana Mircheva, Michael R. Edwards, Sebastian L. Johnston, Krassimir Kalinov, Rainer Stange, Giuseppe Gancitano, Wim Vanden Berghe, Samo Kreft
doi: https://doi.org/10.1101/2021.12.10.21267582
Emil Kolev
1Clinical Research Center DCC Convex Ltd., 11 A Sinanishko ezero, Str. Sofia 1680, Bulgaria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lilyana Mircheva
1Clinical Research Center DCC Convex Ltd., 11 A Sinanishko ezero, Str. Sofia 1680, Bulgaria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lilly@convex.bg info@convex.bg
Michael R. Edwards
2Virtus Respiratory Research Limited, London Bioscience Innovation Centre, 2 Royal College St, London, NW1 0NH, United Kingdom
3National Heart Lung Institute, Imperial College London St Marys Campus, Norfolk Place London W2 1PG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian L. Johnston
2Virtus Respiratory Research Limited, London Bioscience Innovation Centre, 2 Royal College St, London, NW1 0NH, United Kingdom
3National Heart Lung Institute, Imperial College London St Marys Campus, Norfolk Place London W2 1PG, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krassimir Kalinov
4Medistat Ltd. Statistical Services, Mladost 1A, 1729 Sofia, Bulgaria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rainer Stange
5Charité – Universitätsmedizin Berlin, Immanuel Hospital Berlin, Königstrasse 63, D-14109 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giuseppe Gancitano
61st “Tuscania” Paratrooper Regiment Carabinieri, Italian Ministry of Defence, 57127 Livorno, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wim Vanden Berghe
7Laboratory of Protein Chemistry, Proteomics and Epigenetic Signaling (PPES) and Integrated Personalized and Precision Oncology Network (IPPON), Department of Biomedical Sciences, University of Antwerp (UA), Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samo Kreft
8Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, Ljubljana, Slovenia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction SARS-CoV-2 vaccination is effective in preventing severe COVID-19, but efficacy in reducing viral load and transmission wanes over time. In addition, the emergence of novel SARS-CoV-2 variants increases the threat of uncontrolled dissemination and additional antiviral therapies are urgently needed for effective containment. In previous in vitro studies Echinacea purpurea demonstrated strong antiviral activity against enveloped viruses, including SARS-CoV-2. In this study, we examined the potential of Echinacea purpurea in preventing and treating respiratory tract infections (RTIs) and in particular, SARS-CoV-2 infections.

Methods 120 healthy volunteers (m,f, 18 – 75 years) were randomly assigned to Echinacea prevention or control group without any intervention. After a run-in week, participants went through 3 prevention cycles of 2, 2 and 1 months with daily 2’400mg Echinacea purpurea extract (Echinaforce®, EF). The prevention cycles were interrupted by breaks of 1 week. Acute respiratory symptoms were treated with 4’000 mg EF for up to 10 days, and their severity assessed via a diary. Naso/oropharyngeal swabs and venous blood samples were routinely collected every month and during acute illnesses for detection and identification of respiratory viruses, including SARS-CoV-2 via RT-qPCR and serology.

Results Summarized over all phases of prevention, 21 and 29 samples tested positive for any virus in the EF and control group, of which 5 and 14 samples tested SARS-CoV-2 positive (RR=0.37, Chi-square test, p=0.03). Overall, 10 and 14 symptomatic episodes occurred, of which 5 and 8 were COVID-19 (RR=0.70, Chi-square test, p>0.05). EF treatment when applied during acute episodes significantly reduced the overall virus load by at least 2.12 log10 or approx. 99% (t-test, p<0.05), the time to virus clearance by 8.0 days for all viruses (Wilcoxon test, p=0.02) and by 4.8 days for SARS-CoV-2 (p>0.05) in comparison to control. Finally, EF treatment significantly reduced fever days (1 day vs 11 days, Chi-square test, p=0.003) but not the overall symptom severity. There were fewer COVID-19 related hospitalizations in the EF treatment group (N=0 vs N=2).

Discussion/Conclusion EF exhibited antiviral effects and reduced the risk of viral RTIs, including SARS-CoV-2. By substantially reducing virus loads in infected subjects, EF offers a supportive addition to existing mandated treatments like vaccinations. Future confirmatory studies are warranted.

Clinical Trials registration Nr NCT05002179

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT05002179

Funding Statement

This study did not receive any funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee/IRB of Diagnostics and Consultation Center Convex EOOD gave ethical approval for this work

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 14, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Echinacea purpurea for the Long-term Prevention of Viral Respiratory Tract Infections during COVID-19 Pandemic: A Randomized, Open, Controlled, Exploratory Clinical Study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Echinacea purpurea for the Long-term Prevention of Viral Respiratory Tract Infections during COVID-19 Pandemic: A Randomized, Open, Controlled, Exploratory Clinical Study
Emil Kolev, Lilyana Mircheva, Michael R. Edwards, Sebastian L. Johnston, Krassimir Kalinov, Rainer Stange, Giuseppe Gancitano, Wim Vanden Berghe, Samo Kreft
medRxiv 2021.12.10.21267582; doi: https://doi.org/10.1101/2021.12.10.21267582
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Echinacea purpurea for the Long-term Prevention of Viral Respiratory Tract Infections during COVID-19 Pandemic: A Randomized, Open, Controlled, Exploratory Clinical Study
Emil Kolev, Lilyana Mircheva, Michael R. Edwards, Sebastian L. Johnston, Krassimir Kalinov, Rainer Stange, Giuseppe Gancitano, Wim Vanden Berghe, Samo Kreft
medRxiv 2021.12.10.21267582; doi: https://doi.org/10.1101/2021.12.10.21267582

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (135)
  • Cardiovascular Medicine (1749)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (654)
  • Epidemiology (10785)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2935)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1919)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12501)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (322)
  • Neurology (2785)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (556)
  • Occupational and Environmental Health (597)
  • Oncology (1458)
  • Ophthalmology (441)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (334)
  • Psychiatry and Clinical Psychology (2633)
  • Public and Global Health (5342)
  • Radiology and Imaging (1004)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (724)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)